Susan Moran
Director/Board Member en BIOATLA, INC. .
Fortuna: - $ al 31/03/2024
Perfil
Susan Moran is an Independent Director at BioAtla, Inc. and the Chief Medical Officer at QED Therapeutics, Inc. She previously worked as a Medical Director at Millennium Pharmaceuticals, Inc., a Senior Medical Director at Genzyme Therapeutics Ltd., and as the Vice President & Head-Clinical Development at Puma Biotechnology, Inc. Dr. Moran's education includes an undergraduate degree from the University of Virginia, an undergraduate degree from Duke University, and a graduate degree from the University of Pennsylvania Medical Center.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
BIOATLA, INC.
-.--% | 14/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Susan Moran
Empresas | Cargo | Inicio |
---|---|---|
BIOATLA, INC. | Director/Board Member | 01/12/2020 |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Chief Tech/Sci/R&D Officer | 01/03/2018 |
Antiguos cargos conocidos de Susan Moran.
Empresas | Cargo | Fin |
---|---|---|
RAYZEBIO, INC. | Chief Tech/Sci/R&D Officer | 26/02/2024 |
PUMA BIOTECHNOLOGY, INC. | Chief Tech/Sci/R&D Officer | 01/02/2018 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/01/2014 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Chief Tech/Sci/R&D Officer | 01/01/2011 |
Formación de Susan Moran.
University of Virginia | Undergraduate Degree |
Duke University | Undergraduate Degree |
University of Pennsylvania Medical Center | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
BIOATLA, INC. | Health Technology |
PUMA BIOTECHNOLOGY, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
- Bolsa de valores
- Insiders
- Susan Moran